The use of ranolazine in the treatment of coronary heart disease

Abstract

The paper presents the study of a new anti-anginal drug - sodium channel inhibitor ranolazine. Considered antianginal, anti-ischemic effect of the drug. Described reduction in angina attacks, increased exercise tolerance and quality of life of patients with stable angina during treatment with ranolazine. Discusses indications, contraindications, side effects, as well as the major clinical trials of the drug ranolazine in patients with coronary heart disease.

Keywords

• ischemic heart disease
• angina
• acute coronary syndrome
• antianginal therapy
• quality of life
• ranolazine
• raneksa® inhibitor of late sodium current channels